Revolution Medicines’ Experimental Cancer Drug Shows Significant Survival Benefit in Pancreatic Cancer Trial

On April 13, 2026, Revolution Medicines announced positive results from a Phase III clinical trial of its experimental oral drug, daraxonrasib, for patients with previously treated metastatic pancreatic cancer. The data showed that daraxonrasib nearly doubled overall survival compared to standard care, marking a potential advancement in the treatment of this aggressive disease.

Pancreatic cancer remains one of the most challenging cancers to treat, with a five-year survival rate of approximately 13%. The lack of effective screening methods often leads to late-stage diagnosis, and the disease’s resistance to conventional therapies further complicates treatment efforts. Daraxonrasib is designed to target the RAS protein, which is frequently mutated in pancreatic cancers and plays a key role in tumor growth and survival.

In the trial, patients receiving daraxonrasib experienced a statistically significant improvement in survival duration. Lead trial researcher Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at the Dana-Farber Cancer Institute, described the results as a meaningful advance for the field, noting the potential for practice-changing impact on patient care.

The U.S. Food and Drug Administration is expected to review daraxonrasib for potential approval in the coming months. If approved, it could develop into the first targeted therapy of its kind available for metastatic pancreatic cancer, offering a new option for patients who have limited treatment alternatives after initial therapies fail.

Revolution Medicines continues to develop daraxonrasib and other investigational agents focused on RAS-driven cancers, with the goal of expanding precision medicine approaches for difficult-to-treat malignancies.

Key Takeaways

• Daraxonrasib, an experimental oral drug from Revolution Medicines, showed a near-doubling of survival in a Phase III trial for metastatic pancreatic cancer.
• The drug targets the RAS protein, a critical driver in many pancreatic cancers.
• Results were presented by lead researcher Brian Wolpin of the Dana-Farber Cancer Institute.
• FDA review is anticipated within months, with potential approval offering a new treatment option.
• Pancreatic cancer remains difficult to treat due to late diagnosis and therapy resistance, underscoring the need for innovative approaches.

Frequently Asked Questions

What is daraxonrasib?

Daraxonrasib is an experimental oral medication developed by Revolution Medicines that inhibits the RAS protein, which is commonly mutated in pancreatic and other cancers.

How does daraxonrasib operate?

The drug is designed to block abnormal RAS signaling, which contributes to uncontrolled cancer cell growth, thereby slowing or stopping tumor progression.

Who might benefit from daraxonrasib?

The clinical trial focused on patients with previously treated metastatic pancreatic cancer, meaning their cancer had spread and did not respond to standard therapies.

When could daraxonrasib be available?

Pending successful FDA review, which is expected within months of the April 2026 trial results, the drug could become available to patients shortly thereafter.

Why is pancreatic cancer hard to treat?

Pancreatic cancer is often diagnosed at an advanced stage due to the absence of early symptoms and reliable screening tests. It also tends to resist standard chemotherapy, partly as of the dense tissue surrounding tumors that limits drug penetration.